Omadacycline, a new-generation tetracycline, was approved in 2018 by the FDA to treat adults with acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia.
Early treatment with oseltamivir in the ICU was associated with significantly lower mortality rates in patients with influenza A/H3N2 but appeared to have no effect in patients with influenza A/H1N1 or B.
Barriers in the medical ICU included insufficient visibility of the intervention and low investment among medical residents due to frequent rotation and competing priorities, researchers found.
More medications in advanced life-limiting illness can lower quality of life, increase symptom burden
Polypharmacy may be particularly burdensome near the end of life as patients accumulate medications to treat and prevent multiple diseases.